

---

## Nikolaos G. Papadopoulos *Curriculum Vitae*

---

75, El.Venizelou, 15561, Holargos, Greece	CURRENT POSITION
Tel: +30 6940773946, +44 7870 529408 Email: <a href="mailto:ngp@allergy.gr">ngp@allergy.gr</a>	Professor of Allergy and Paediatric Allergy, University of Athens, Greece & University of Manchester UK

EDUCATION			
INSTITUTION	DEGREE	YEAR	FIELD
Medical School, University of Athens (NKUA)	MD	1989	Medicine
Medical School, NKUA	PhD	1992	Immunology, Inf.Diseases
2 <sup>nd</sup> Pediatric Clinic, NKUA	Specialty	1997	Paediatrics
Allergy Department, 2 <sup>nd</sup> Pediatric Clinic, NKUA	Specialty	2001	Allergology

LANGUAGES: English (fluent), Greek (fluent), Spanish (fluent), French (basic)

---

### A. Posts & Distinctions

#### Posts

##### **Academic:**

##### **National and Kapodistrian University of Athens, NKUA:**

2001 – 2003: Research Fellow. Head of the Allergy Research Laboratory

2003 – 2008: Lecturer in Pediatrics - Allergology

2008 – 2010: Assistant Professor in Pediatrics - Allergology

2010 – 2015: Associate Professor in Allergology – Pediatric Allergology

2015 – ... Professor in Allergology – Pediatric Allergology

##### **University of Manchester:**

2014 – ... Professor of Allergy & Paediatric Allergy

##### **Clinical:**

2003 – 2007: Consultant, Allergy Dpt. University Pediatric Clinic, P&A Kyriakou Children's Hospital, Athens

2007 – 2015: Head, Allergy Dpt, University Pediatric Clinic, P&A Kyriakou Children's Hospital, Athens

2015 – 2019: Honorary Consultant, Central Manchester Foundation Trust

#### Leadership positions (selection)

- Respiratory Effectiveness Group (REG), President 2017-9
- European Academy of Allergy and Clinical Immunology (EAACI), President 2013-2015
- Global Allergy and Asthma European Network (GA2LEN), Executive Committee member, 2004-2005, 2013-
- World Allergy Organisation (WAO), Communication Council Member 2007-2009
- Allergic Rhinitis & its Impact on Asthma (ARIA), International Advisory Committee, 2002 –
- American Academy of Allergy, Asthma and Immunology (AAAAI), Fellow, 2006 –
- National Hellenic Examination Committee for Specialization Allergology, Chair (2011-)

#### Awards

- Clemens von Pirquet Award, EAACI 2019
  - Phadia Allergy Research Foundation Award, 2010
  - European Respiratory Society (ERS) Annual Award for Pediatric Asthma Research 2004
  - Empirikion National Award, 2004
  - Klosterfrau International Award for Pediatric Asthma, 2003
  - Pharmacia Allergy Research Foundation International Award - Honorable Mention, 2001
  - Innovative Research European Academy of Allergy and Clinical Immunology (EAACI), 2000.
  - Respiratory 2000 International Young Investigator Award, 2000.
  - 33 best paper awards in Congresses
-

## B. Invited presentations, publications

**Invited presentations: >300, Chair: >120**

**Publications - <https://scholar.google.com/citations?hl=en&user=sc0m4EUAAAAJ>**

Papers: >320, Book Chapters: >66

Total citations: >32000, H-index: 77 (Google Scholar)

1. Potaczek DP et al. Development and characterization of DNzyme candidates demonstrating significant efficiency against human rhinoviruses. *J Allergy Clin Immunol*. 2019;143(4):1403-15
2. Roche N et al. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group. *Eur Respir J* 2019;54:1901511
3. Megremis S et al. Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma. *Am J Respir Crit Care Med*. 2018 Aug 22. doi: 10.1164/rccm.201803-0575OC.
4. Chairakaki HA et al. Plasmacytoid dendritic cells drive acute asthma exacerbations. *J Allergy Clin Immunol* 2018;142(2):542-556
5. Niespodziana K, et al. PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze. *Nat Commun*. 2018; 9:2382
6. Graser, A., et al., Rhinovirus inhibits IL-17A and the downstream immune responses in allergic asthma. *Mucosal Immunol*, 2016.
7. Skevaki, C.L., et al., Associations between Viral and Bacterial Potential Pathogens in the Nasopharynx of Children with and Without Respiratory Symptoms. *Pediatr Infect Dis J*, 2015.
8. Mazur, N.I., et al., Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. *Lancet Respir Med*, 2015. **3**(11): p. 888-900.
9. Jackson, D.J., et al., IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. *Am J Respir Crit Care Med*, 2014. **190**(12): p. 1373-82.
10. Andreakos, E. and N.G. Papadopoulos, IL-25: the missing link between allergy, viral infection, and asthma? *Sci Transl Med*, 2014. **6**(256): p. 256fs38.
11. Konstantinou, G.N., et al., Assessment of airflow limitation, airway inflammation, and symptoms during virus-induced wheezing episodes in 4- to 6-year-old children. *J Allergy Clin Immunol*, 2013. **131**(1): p. 87-93 e1-5.
12. Papadopoulos, N.G., et al., International consensus on (ICON) pediatric asthma. *Allergy*, 2012. **67**(8): p. 976-97.
13. Niespodziana, K., et al., Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. *FASEB J*, 2012. **26**(3): p. 1001-8.
14. Megremis, S., et al., The genomic signature of human rhinoviruses A, B and C. *PLoS One*, 2012. **7**(9): p. e44557.
15. Xatzipsalti, M., et al., Modulation of the epithelial inflammatory response to rhinovirus in an atopic environment. *Clin Exp Allergy*, 2008. **38**(3): p. 466-72.
16. Psarras, S., et al., Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. *J Allergy Clin Immunol*, 2006. **117**(2): p. 291-7.
17. Xepapadaki, P., et al., Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. *J Allergy Clin Immunol*, 2005. **116**(2): p. 299-304.
18. Xatzipsalti, M., et al., Rhinovirus viremia in children with respiratory infections. *Am J Respir Crit Care Med*, 2005. **172**: 1037-40.
19. Papi, A., et al., Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells. *FASEB J*, 2002. **16**(14): p. 1934-6.
20. Papadopoulos, N.G., et al., A defective type 1 response to rhinovirus in atopic asthma. *Thorax*, 2002. **57**(4): p. 328-32.
21. Papadopoulos, N.G., et al., Association of rhinovirus infection with increased disease severity in acute bronchiolitis. *Am J Respir Crit Care Med*, 2002. **165**(9): p. 1285-9.
22. Papadopoulos, N.G., et al., Rhinoviruses infect the lower airways. *J Infect Dis*, 2000. **181**(6): p. 1875-84.

## C. Research funding (selection)

- CURE – H2020 (Coordinator): Constructing a ‘Eubiosis Reinstatement Therapy’ for Asthma (2017-2021) – 3,000,000€
- PreDicta – FP7 (Coordinator): Post infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases. Contract No: HEALTH-F2-2010260895. (2010-2015). – 6,000,000€.
- EARIP-FP7 – (WP leader): European Asthma Research and Innovation Partnership. (2013-2016) Contract No:HEALTH-2013-INNOVATION-602077. – 500,000€.
- MIDAS (Co-PI): Maturity of non-specific immunity: influence of infections and their role in the development of atopy and asthma (2012-2015) – 600,000€.
- GA2LEN–FP6 Network of Excellence – (WP Leader): Global Allergy and Asthma European Network. Contract No: FOOD-CT-2004-506378 (2004-2008). 15,000,000€.